← stocks-llm Find companies like SENS →

SENSEONICS HOLDINGS INC (SENS)

Health Care · Implantable Medical Devices / Diabetes Management · NASDAQ

Senseonics develops implantable continuous glucose monitoring systems that stay under the skin for up to one year, offering diabetes patients longer intervals between sensor replacements than conventional CGM devices.

What SENSEONICS HOLDINGS INC does

Senseonics is a medical technology company developing and commercializing Eversense, a long-term implantable continuous glucose monitoring (CGM) system for diabetes management. The company's flagship products—Eversense E3 (6-month wear) and Eversense 365 (12-month wear)—use an under-the-skin sensor with a removable rechargeable smart transmitter and mobile app to continuously measure and report glucose levels. As of January 2026, Senseonics took direct commercial responsibility for U.S. marketing and distribution after previously partnering with Ascensia; the company also markets internationally through selective distribution partnerships and is developing next-generation variants including Gemini (2-in-1 glucose/flash monitoring) and Freedom (Bluetooth-enabled sensor without separate transmitter).

Themes: ["Implantable continuous glucose monitoring (CGM)","Long-term diabetes management","Medical devices for diabetes"]

Fundamentals

Ask why SENS looks like this →

Key risks (from latest filing)

[]

See SENS's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.